In a report issued on May 24, Daniel Busby from RBC Capital maintained a Buy rating on Xeris Pharmaceuticals (XERS), with a price target of $10.00. The company’s shares closed last Tuesday at $3.30, close to its 52-week low of $2.45.
According to TipRanks.com, Busby is a 2-star analyst with an average return of 0.8% and a 58.3% success rate. Busby covers the Healthcare sector, focusing on stocks such as Osmotica Pharmaceuticals, Verrica Pharmaceuticals, and Aquestive Therapeutics.
Currently, the analyst consensus on Xeris Pharmaceuticals is a Strong Buy with an average price target of $8.00, implying a 146.9% upside from current levels. In a report issued on May 14, Mizuho Securities also assigned a Buy rating to the stock with a $14.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.94 and a one-year low of $2.45. Currently, Xeris Pharmaceuticals has an average volume of 2.38M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.